OCGNOcugen, Inc.
$0.98-44% 1Y
$0.98
$0.9852 weeks$2.48
Latest close: a new 52-week lowOct 8, 2026what changed →
OCGN in its own filings
OCGN's filing record carries 4 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
386
Events found in the filings · across 886 filings · the record starts in 2014
- Hard flags
- 4
Hard flags
- Most recent filing
- Oct 6, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 13, 2014
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Restatement admitted (non-reliance)past_3y
- 2024-04-01
- Change in certifying accountant3 occurrences
- 2024-07-08
- Late periodic report2 occurrences
- 2024-04-01
- Delisting notice / listing-rule failure15 occurrences
- 2025-07-01
- SEC comment-letter activity29 occurrences
- 2025-02-11
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026On September 1, 2026, the Company announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for Geographic Atrophy (“GA”) secondary to dry age-related macular degeneration (“dAMD”)Regulation FD disclosure · Form 8-K
- Aug 6, 2026Ocugen Provides Business Update with Second.Earnings release · press release
- Jul 13, 2026On July 13, 2026, Ocugen, Inc. (the “Company”) issued a press release announcing that it signed a binding term sheet for the license of OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa.Other event · Form 8-K
- Jun 11, 2026As previously reported, effective May 8, 2026, the Company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer. The Company appointed Dr. Genead as Chief Medical Officer effective as of June 11, 2026.Shareholder vote results · Form 8-K
- Jun 3, 2026Effective May 29, 2026, Ramesh Ramachandran, CPA, MBA, CMA, resigned as the Chief Accounting Officer of Ocugen, Inc. (the “Company”)Director or officer change · Form 8-K
- May 14, 2026Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.Director or officer change · Form 8-K
- May 14, 2026As previously reported, on May 7, 2026, Ocugen, Inc. (the “Company”) completed the closing under its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”)New debt or off-balance-sheet obligation · Form 8-K
- May 7, 2026Indenture and Notes On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”)Material agreement entered · Form 8-K
- May 5, 2026On May 5, 2026, the Company announced the pricing of its previously announced private offering (the “Offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “Notes”)Earnings release · Form 8-K
- May 4, 2026On May 4, 2026, the Company issued a press release announcing the Offering.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…